DRUG — Bright Minds Biosciences Inc. stock price, charts and financials
QT65Bright Minds Biosciences Inc.Bright Minds Biosciences Inc. (NASDAQ: DRUG) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 10.82% | Shs Outstand | 9.79M | Perf Week | -3.48% |
| Market Cap | 598.48M | Forward P/E | - | EPS next Y | -6.35 | Insider Trans | -10.32% | Shs Float | 6.11M | Perf Month | -28.04% |
| Enterprise Value | 378.23M | PEG | 0.40 | EPS next Q | -0.77 | Inst Own | - | Short Float | 14.63% | Perf Quarter | 0.53% |
| Income | -17.60M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 3.14 | Perf Half Y | -15.63% |
| Sales | 0.00 | P/B | 2.73 | EPS next Y | -141.78% | ROA | -7.96% | Short Interest | 893.57K | Perf YTD | -21.86% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -12.56% | 52W High | 123.74 -50.72% | Perf Year | 36.48% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -12.92% | 52W Low | 44.28 37.71% | Perf 3Y | 3424.86% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 3.67% 4.46% | Perf 5Y | 119.04% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -335.28% | Oper. Margin | 0.00% | ATR (14) | 3.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 121.97 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 32.85 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 121.97 | EPS Q/Q | 67.92% | SMA20 | -10.99% | Beta | -4.64 | Target Price | 182.50 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -16.92% | Rel Volume | 0.75 | Prev Close | 61.55 |
| Employees | 26 | LT Debt/Eq | - | Earnings | Dec 22 | SMA200 | -21.68% | Avg Volume | 190.20K | Price | 60.98 |
| IPO Date | Mar 22, 2021 | Option/Short | No / Yes | EPS/Sales Surpr. | 86.46% - | Net Debt/EBITDA | 7.75 | Volume | 142,282 | Change | -0.93% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-01-26 | Reiterated | HC Wainwright & Co. | Buy | $85 → $145 |
| May-20-26 | Reiterated | Piper Sandler | Overweight | $220 |
| Feb-13-26 | Reiterated | Robert W. Baird | $142 → $126 | |
| Jan-07-26 | Reiterated | Robert W. Baird | $82 → $142 | |
| Jan-07-26 | Reiterated | BTIG | Buy | $147 |
| Jan-06-26 | Reiterated | BTIG | Buy | $147 |
| May-07-25 | Initiated | Chardan | Buy | $80 |
| Jan-10-25 | Initiated | H.C | Buy | $85 |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 9/30/2025 | FY 2024 9/30/2024 | FY 2023 9/30/2023 | FY 2022 9/30/2022 | FY 2021 9/30/2021 | FY 2020 9/30/2020 | FY 2019 9/30/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 2 | 1 | 2 | — | — | — | — | |
| Research and Development | 8 | 1 | 4 | — | — | — | — | |
| Other Operating Expense | 0 | 0 | -1 | — | — | — | — | |
| Operating Income | -10 | -2 | -5 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1 | 0 | 0 | — | — | — | — | |
| Net Income Before Taxes | -9 | -2 | -5 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -9 | -2 | -5 | — | — | — | — | |
| Net Income From Continuing Operations | -9 | -2 | -5 | — | — | — | — | |
| Net Income | -9 | -2 | -5 | — | — | — | — | |
| EPS (Recurring) | -1.27 | -0.48 | -1.47 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.27 | -0.48 | -1.47 | — | — | — | — | |
| EPS (Diluted) | -1.27 | -0.48 | -1.47 | — | — | — | — | |
| EBITDA | -9 | -2 | -5 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 7 | 4 | 4 | — | — | — | — | |
| Market Capitalization | 425 | 5 | 6 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | other: Former 10% Owner | Apr 28 '26 | Sale | 89.50 | 109,331 | 9,785,125 | 950,000 | Apr 30 |
| Cormorant Asset Management, LP | 10% Owner | Nov 04 '24 | Buy | 21.70 | 184,331 | 3,999,983 | 1,059,331 | Nov 06 |
| Cormorant Asset Management, LP | 10% Owner | Oct 16 '24 | Buy | 23.46 | 50,000 | 1,172,814 | 875,000 | Oct 17 |
| Cormorant Asset Management, LP | 10% Owner | Oct 15 '24 | Buy | 5.53 | 372,591 | 2,061,573 | 825,000 | Oct 17 |